Kung-Chu Ho1,2, Yu-Hua Dean Fang3, Hsiao-Wen Chung1, Yuan-Chang Liu4, John Wen-Cheng Chang5, Ming-Mo Hou5, Cheng-Ta Yang6, Nai-Ming Cheng2, Tzu-Pei Su7, Tzu-Chen Yen8. 1. Graduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University, Taipei, Taiwan. 2. Department of Nuclear Medicine and Center for Advanced Molecular Imaging and Translation, Chang Gung Memorial Hospital and Chang Gung University, 5 Fu-Shin Street, Kueishan, Taoyuan, 333, Taiwan. 3. Department of Biomedical Engineering, National Cheng Kung University, Tainan, Taiwan. 4. Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan. 5. Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan. 6. Department of Thoracic Medicine, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan. 7. Department of Nuclear Medicine, Chang Gung Memorial Hospital, Keelung, Taiwan. 8. Department of Nuclear Medicine and Center for Advanced Molecular Imaging and Translation, Chang Gung Memorial Hospital and Chang Gung University, 5 Fu-Shin Street, Kueishan, Taoyuan, 333, Taiwan. yen1110@adm.cgmh.org.tw.
Abstract
PURPOSE: In this retrospective review of prospectively collected data, we sought to investigate whether early FDG-PET assessment of treatment response based on total lesion glycolysis measured using a systemic approach (TLG-S) would be superior to either local assessment with EORTC (European Organization for Research and Treatment of Cancer) criteria or single-lesion assessment with PERCIST (PET Response Criteria in Solid Tumors) for predicting clinical outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib. We also examined the effect of bone flares on tumor response evaluation by single-lesion assessment with PERCIST in patients with metastatic bone lesions. METHODS: We performed a retrospective review of prospectively collected data from 23 patients with metastatic lung adenocarcinoma treated with erlotinib. All participants underwent FDG-PET imaging at baseline and on days 14 and 56 after completion of erlotinib treatment. In addition, diagnostic CT scans were performed at baseline and on day 56. FDG-PET response was assessed with TLG-S, EORTC, and PERCIST criteria. Response assessment based on RECIST 1.1 (Response Evaluation Criteria in Solid Tumors) from diagnostic CT imaging was used as the reference standard. Two-year progression-free survival (PFS) and overall survival (OS) served as the main outcome measures. RESULTS: We identified 13 patients with bone metastases. Of these, four (31 %) with persistent bone uptake due to bone flares on day 14 were erroneously classified as non-responders according to the PERCIST criteria, but they were correctly classified as responders according to both the EORTC and TLG-S criteria. Patients who were classified as responders on day 14 based on TLG-S criteria had higher rates of 2-year PFS (26.7 % vs. 0 %, P = 0.007) and OS (40.0 % vs. 7.7 %, P = 0.018). Similar rates were observed in patients who showed a response on day 56 based on CT imaging according to the RECIST criteria. Patients classified as responders on day 14 according to the EORTC criteria on FDG-PET imaging had better rates of 2-year OS than did non-responders (36.4 % vs. 8.3 %, P = 0.015). CONCLUSIONS: TLG-S criteria may be of greater help in predicting survival outcomes than other forms of assessment. Bone flares, which can interfere with the interpretation of treatment response based on PERCIST criteria, are not uncommon in patients with metastatic lung adenocarcinoma treated with erlotinib.
PURPOSE: In this retrospective review of prospectively collected data, we sought to investigate whether early FDG-PET assessment of treatment response based on total lesion glycolysis measured using a systemic approach (TLG-S) would be superior to either local assessment with EORTC (European Organization for Research and Treatment of Cancer) criteria or single-lesion assessment with PERCIST (PET Response Criteria in Solid Tumors) for predicting clinical outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib. We also examined the effect of bone flares on tumor response evaluation by single-lesion assessment with PERCIST in patients with metastatic bone lesions. METHODS: We performed a retrospective review of prospectively collected data from 23 patients with metastatic lung adenocarcinoma treated with erlotinib. All participants underwent FDG-PET imaging at baseline and on days 14 and 56 after completion of erlotinib treatment. In addition, diagnostic CT scans were performed at baseline and on day 56. FDG-PET response was assessed with TLG-S, EORTC, and PERCIST criteria. Response assessment based on RECIST 1.1 (Response Evaluation Criteria in Solid Tumors) from diagnostic CT imaging was used as the reference standard. Two-year progression-free survival (PFS) and overall survival (OS) served as the main outcome measures. RESULTS: We identified 13 patients with bone metastases. Of these, four (31 %) with persistent bone uptake due to bone flares on day 14 were erroneously classified as non-responders according to the PERCIST criteria, but they were correctly classified as responders according to both the EORTC and TLG-S criteria. Patients who were classified as responders on day 14 based on TLG-S criteria had higher rates of 2-year PFS (26.7 % vs. 0 %, P = 0.007) and OS (40.0 % vs. 7.7 %, P = 0.018). Similar rates were observed in patients who showed a response on day 56 based on CT imaging according to the RECIST criteria. Patients classified as responders on day 14 according to the EORTC criteria on FDG-PET imaging had better rates of 2-year OS than did non-responders (36.4 % vs. 8.3 %, P = 0.015). CONCLUSIONS:TLG-S criteria may be of greater help in predicting survival outcomes than other forms of assessment. Bone flares, which can interfere with the interpretation of treatment response based on PERCIST criteria, are not uncommon in patients with metastatic lung adenocarcinoma treated with erlotinib.
Authors: M E R O'Brien; J S Myerson; J I G Coward; M Puglisi; L Trani; A Wotherspoon; B Sharma; G Cook; S Ashley; R Gunapala; S Chua; S Popat Journal: Eur J Cancer Date: 2011-11-24 Impact factor: 9.162
Authors: Linda Mileshkin; Rodney J Hicks; Brett G M Hughes; Paul L R Mitchell; Veena Charu; Barbara J Gitlitz; David Macfarlane; Benjamin Solomon; Lukas C Amler; Wei Yu; Andrea Pirzkall; Bernard M Fine Journal: Clin Cancer Res Date: 2011-03-01 Impact factor: 12.531
Authors: Matthias R Benz; Ken Herrmann; Franziska Walter; Edward B Garon; Karen L Reckamp; Robert Figlin; Michael E Phelps; Wolfgang A Weber; Johannes Czernin; Martin S Allen-Auerbach Journal: J Nucl Med Date: 2011-11 Impact factor: 10.057
Authors: H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price Journal: Eur J Cancer Date: 1999-12 Impact factor: 9.162
Authors: Steven M. Larson; Yusuf Erdi; Timothy Akhurst; Madhu Mazumdar; Homer A. Macapinlac; Ronald D. Finn; Cecille Casilla; Melissa Fazzari; Neil Srivastava; Henry W.D. Yeung; John L. Humm; Jose Guillem; Robert Downey; Martin Karpeh; Alfred E. Cohen; Robert Ginsberg Journal: Clin Positron Imaging Date: 1999-05
Authors: A Kalikaki; A Koutsopoulos; M Trypaki; J Souglakos; E Stathopoulos; V Georgoulias; D Mavroudis; A Voutsina Journal: Br J Cancer Date: 2008-09-16 Impact factor: 7.640
Authors: Claudio R Scafoglio; Brendon Villegas; Gihad Abdelhady; Sean T Bailey; Jie Liu; Aditya S Shirali; W Dean Wallace; Clara E Magyar; Tristan R Grogan; David Elashoff; Tonya Walser; Jane Yanagawa; Denise R Aberle; Jorge R Barrio; Steven M Dubinett; David B Shackelford Journal: Sci Transl Med Date: 2018-11-14 Impact factor: 17.956
Authors: Joan Fledelius; Anne Winther-Larsen; Azza A Khalil; Karin Hjorthaug; Jørgen Frøkiær; Peter Meldgaard Journal: Am J Nucl Med Mol Imaging Date: 2018-02-05
Authors: Aurélien Justet; Astrid Laurent-Bellue; Gabriel Thabut; Arnaud Dieudonné; Marie-Pierre Debray; Raphael Borie; Michel Aubier; Rachida Lebtahi; Bruno Crestani Journal: Respir Res Date: 2017-04-27
Authors: Charline Lasnon; Elske Quak; Pierre-Yves Le Roux; Philippe Robin; Michael S Hofman; David Bourhis; Jason Callahan; David S Binns; Cédric Desmonts; Pierre-Yves Salaun; Rodney J Hicks; Nicolas Aide Journal: EJNMMI Phys Date: 2017-05-30